Provided by Tiger Trade Technology Pte. Ltd.

Kymera Therapeutics, Inc.

118.63
-0.4200-0.35%
Post-market: 118.630.00000.00%19:48 EDT
Volume:982.97K
Turnover:117.49M
Market Cap:9.86B
PE:-36.93
High:123.54
Open:119.58
Low:117.42
Close:119.05
52wk High:130.05
52wk Low:39.84
Shares:83.15M
Float Shares:64.87M
Volume Ratio:1.75
T/O Rate:1.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.2122
EPS(LYR):-3.6900
ROE:-24.15%
ROA:-15.59%
PB:6.54
PE(LYR):-32.15

Loading ...

Kymera Therapeutics to Participate in Upcoming September Investor Conferences

GlobeNewswire
·
9 hours ago

Kymera's KT-621 Has 'Oral Dupixent' Potential, but Valuation Limits Upside, RBC Says

MT Newswires Live
·
Yesterday

U.S. Research Roundup-Adobe, Dell Technologies, Zscaler

Reuters
·
Yesterday

Kymera Therapeutics, Inc. : JP Morgan Raises Target Price to $140 from $121

THOMSON REUTERS
·
Yesterday

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral Stat6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

THOMSON REUTERS
·
Sep 01

Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses

GlobeNewswire
·
Sep 01

Kymera Therapeutics Price Target Raised to $151.00/Share from $116.00 by Wells Fargo

Dow Jones
·
Aug 27

Kymera Therapeutics Speeds Pipeline Amid Rising Spend

TIPRANKS
·
Aug 21

Kymera Therapeutics on Track for Record High Closing

Dow Jones
·
Aug 17

Kymera Therapeutics (KYMR) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Aug 13

Analysts’ Top Healthcare Picks: Metagenomi, Inc. (MGX), Kymera Therapeutics (KYMR)

TIPRANKS
·
Aug 11

Immunic Appoints Elena Ridloff to Board of Directors

Reuters
·
Aug 11

Nurix Therapeutics' STAT6 Degrader Likely to Receive Increased Recognition, RBC Says

MT Newswires Live
·
Aug 11

Halozyme Q2 Revenue Jumps 48%, Raises 2026 Outlook

Reuters
·
Aug 07

Analyst Reiterates Buy on Kymera, Citing Favorable BROADEN2 Design and Compelling KT-621 Risk-Reward in Atopic Dermatitis

TIPRANKS
·
Aug 06

Kymera Therapeutics, Inc. : Citigroup Raises Target Price to $135 from $120

THOMSON REUTERS
·
Aug 06

Kymera Therapeutics price target raised to $139 from $133 at Barclays

TIPRANKS
·
Aug 06

Tenaya Therapeutics Q2 Net Loss Widens on Impairment Charge

Reuters
·
Aug 06

Vir Biotechnology Q2 Revenue Up, Beats Estimates on Astellas Payment

Reuters
·
Aug 06

Biopharma Firm Xencor's Q2 Revenue Beats on Royalty Revenue, Milestone Payments

Reuters
·
Aug 06